Q2 2026 13F · SEC CIK 1969764
Propel Bio Management, LLC
Hedge fundFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $191.1M
- Reported positions
- 29
- Top holdings a year, 3 yrs
- +13.1%
- Assets under management
- $247.5M
Propel Bio Management, LLC is a hedge fund that reported 29 positions worth $191.1M in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Plains Gp Hldgs L P (PAGP, 16.2%), Achieve Life Science Inc (ACHV, 13.8%), Corcept Therapeutics Inc (CORT, 6.2%). A portfolio copying its top holdings returned 13.1% a year over the last 3 years, against 18.8% for the S&P 500.
Propel Bio Management, LLC holdings all 29 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
What Propel Bio Management, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- Immunic Inc2.6% of 13F
- SCYX Scynexis Inc1.2% of 13F
- SLN Silence Therapeutics PLC1.1% of 13F
- SGMT Sagimet Biosciences Inc0.5% of 13F
Added to
- ARTV Artiva Biotherapeutics Inc+375.8% shares
- PALI Palisade Bio Inc+131.6% shares
- AQST Aquestive Therapeutics Inc+102.9% shares
- MIST Milestone Pharmaceuticals in+80.4% shares
- IVA Inventiva SA+76.8% shares
- KYTX Kyverna Therapeutics Inc.+37.1% shares
- PHAT Phathom Pharmaceuticals Inc Com+24.9% shares
- OVID Ovid Therapeutics Inc+21.1% shares
Reduced
- FDMT 4d Molecular Therapeutics in-33.6% shares
- ABEO Abeona Therapeutics-26.1% shares
- CMPS Compass Pathways PLC-22.8% shares
- CLDX Celldex Therapeutics Inc New-21.1% shares
- CRVS Corvus Pharmaceuticals Inc Com-18.0% shares
- EYPT Eyepoint Pharmaceuticals Inc-11.2% shares
- DCTH Delcath Sys Inc-11.0% shares
- ZVRA Zevra Therapeutics Inc-10.2% shares
Sold out
- VOR Vor Biopharma Incwas 3.5%
- VRDN Viridian Therapeutics Incwas 2.6%
- OCS Oculis Holding AGwas 2.1%
- TRVI Trevi Therapeutics Incwas 1.7%
- Immunic Incwas 1.7%
- CHRS Coherus Oncology Incwas 1.5%
- Kalaris Therapeutics Inc Comwas 1.1%
- QURE Uniqure NVwas 1.1%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +54.7% /yr
- S&P 500 +20.1%
- 3 years
- +13.1% /yr
- S&P 500 +18.8%
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $191.1M | 29 |
| Q1 2026 | $158.7M | 38 |
| Q4 2025 | $117.1M | 20 |
| Q3 2025 | $99.9M | 16 |
| Q2 2025 | $82.4M | 16 |
| Q1 2025 | $86.1M | 18 |
| Q4 2024 | $100.7M | 21 |
| Q3 2024 | $172.4M | 21 |
| Q2 2024 | $154.2M | 24 |
| Q1 2024 | $171.8M | 28 |
| Q4 2023 | $120.6M | 33 |
Questions about Propel Bio Management, LLC's portfolio
What stocks does Propel Bio Management, LLC own?
Propel Bio Management, LLC's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 29 positions worth $191.1M. The largest are Plains Gp Hldgs L P (PAGP) at 16.2%, Achieve Life Science Inc (ACHV) at 13.8%, Corcept Therapeutics Inc (CORT) at 6.2%, Phathom Pharmaceuticals Inc Com (PHAT) at 6.0% and Delcath Sys Inc (DCTH) at 5.7%.
What did Propel Bio Management, LLC buy last quarter?
In Q2 2026, Propel Bio Management, LLC added a new position in Immunic Inc, a new position in Scynexis Inc (SCYX), a new position in Silence Therapeutics PLC (SLN), a new position in Sagimet Biosciences Inc (SGMT), Artiva Biotherapeutics Inc (ARTV) (+375.8% shares), Palisade Bio Inc (PALI) (+131.6% shares) and Aquestive Therapeutics Inc (AQST) (+102.9% shares), compared with its Q1 2026 filing.
What did Propel Bio Management, LLC sell last quarter?
In Q2 2026, Propel Bio Management, LLC sold all of Vor Biopharma Inc (VOR), sold all of Viridian Therapeutics Inc (VRDN), sold all of Oculis Holding AG (OCS), sold all of Trevi Therapeutics Inc (TRVI), sold all of Immunic Inc, 4d Molecular Therapeutics in (FDMT) (-33.6% shares), Abeona Therapeutics (ABEO) (-26.1% shares) and Compass Pathways PLC (CMPS) (-22.8% shares), compared with its Q1 2026 filing.
How has Propel Bio Management, LLC's portfolio performed?
A portfolio copying Propel Bio Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +13.1% a year over the last 3 years, against +18.8% for the S&P 500. Over 1 year: +54.7% against +20.1%.
When is Propel Bio Management, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Propel Bio Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Propel Bio Management, LLC manage?
Propel Bio Management, LLC reported $247.5M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $191.1M.